ASH 2024 – Jorge Castillo

You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

More Information
Unblock content Accept required service and unblock content

Jorge Castillo discusses the relative efficacy and safety of BTK inhibitors with or without BCL2 inhibitors in Waldenström’s macroglobulinemia (WM), highlights important prognostic molecular markers in untreated patients, and reveals new insights into the biology of the disease. He also explores novel therapeutic targets that may shape the future of WM treatment.

Here is the full ASH 2024 report.